A Nomogram to Predict Severe Toxicity in DPYD Wild‐Type Patients Treated With Capecitabine‐Based Anticancer Regimens
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Jonathan E Knikman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Fluorouracil, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
DPYD ‐guided dosing has improved the safety of fluoropyrimidine‐based chemotherapy in recent years. However, severe toxicity remains in ~ 23% of patients not carrying DPYD variant alleles treated with capecitabine. Therefore, we developed a predictive model based on patient‐related and treatment‐related factors aimed at estimating the risk of developing severe capecitabine‐related toxicity. The nomogram was developed using data from two large clinical trials (NCT00838370 and NCT02324452). Patients with cancer carrying a DPYD variant allele ( DPYD *2A, c.1236G>A, c.2846A>T, and c.1679T>G) were excluded. Univariable and multivariable logistic regression using predetermined predictors based on previous findings, including age, sex, body surface area, type of treatment regimen, and creatinine levels were used to develop the nomogram. The developed model was internally validated using bootstrap resampling and cross‐validation. This model was not externally or clinically validated. A total of 2,147 DPYD wild‐type patients with cancer treated with capecitabine‐based chemotherapy regimens were included of which complete data of 1,745 patients were available and used for the development of the nomogram. Univariable and multivariable logistic regression showed that age, sex, and type of treatment regimen were strong predictors of severe capecitabine‐related toxicity in DPYD wild‐type patients. Internal validation demonstrated a concordance index of 0.68 which indicates a good discriminative ability for prediction of severe capecitabine‐related toxicity. The developed nomogram includes readily available parameters and may be a helpful tool for clinicians to assess the risk of developing severe capecitabine‐related toxicity in patients without known risk DPYD variant alleles treated with capecitabine‐based anticancer regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Biometrics Department, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Late Development Oncology, AstraZeneca, Cambridge, UK.
- Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, The Netherlands.
ORCID-Profile: Jonathan E Knikman, Jos Beijnen, Henk-Jan Guchelaar
Zitieren
APA
Knikman, J. E., Lopez-Yurda, M., Meulendijks, D., Deenen, M. J., Schellens, J. H. M., Beijnen, J., Cats, A., & Guchelaar, H. J. (2024). A Nomogram to Predict Severe Toxicity in DPYD Wild‐Type Patients Treated With Capecitabine‐Based Anticancer Regimens. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3100
Vancouver
Knikman JE, Lopez-Yurda M, Meulendijks D, Deenen MJ, Schellens JHM, Beijnen J, et al. A Nomogram to Predict Severe Toxicity in DPYD Wild‐Type Patients Treated With Capecitabine‐Based Anticancer Regimens. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3100
BibTeX
@article{Knikman2024,
author = {Knikman, Jonathan E and Lopez-Yurda, Marta and Meulendijks, Didier and Deenen, Maarten J and Schellens, Jan H M and Beijnen, Jos and Cats, Annemieke and Guchelaar, Henk-Jan},
title = {A Nomogram to Predict Severe Toxicity in DPYD Wild‐Type Patients Treated With Capecitabine‐Based Anticancer Regimens},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3100}
}
EUVIMED